Investigational Drug Information for Narlaprevir
✉ Email this page to a colleague
What is the drug development status for Narlaprevir?
Narlaprevir is an investigational drug.
There have been 7 clinical trials for Narlaprevir.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 7th 2014.
The most common disease conditions in clinical trials are Hepatitis, Hepatitis C, Chronic, and Hepatitis C. The leading clinical trial sponsors are R-Pharm, Almedis, and Merck Sharp & Dohme Corp.
There are two hundred and eight US patents protecting this investigational drug and two international patents.
Summary for Narlaprevir
| US Patents | 208 |
| International Patents | 2,651 |
| US Patent Applications | 448 |
| WIPO Patent Applications | 244 |
| Japanese Patent Applications | 110 |
| Clinical Trial Progress | Phase 3 (2014-05-07) |
| Vendors | 35 |
Recent Clinical Trials for Narlaprevir
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 | Almedis | Phase 2 |
| Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 | ChromSystemsLab | Phase 2 |
| Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 | Scientific Center EFiS | Phase 2 |
Clinical Trial Summary for Narlaprevir
Top disease conditions for Narlaprevir
Top clinical trial sponsors for Narlaprevir
US Patents for Narlaprevir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Narlaprevir | ⤷ Try a Trial | 1',4'-thio nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (Cambridge, MA) | ⤷ Try a Trial |
| Narlaprevir | ⤷ Try a Trial | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | Cocrystal Pharma, Inc. (Tucker, GA) Emory University (Atlanta, GA) | ⤷ Try a Trial |
| Narlaprevir | ⤷ Try a Trial | Benzimidazole derivatives | Enanta Pharmaceuticals, Inc. (Watertown, MA) | ⤷ Try a Trial |
| Narlaprevir | ⤷ Try a Trial | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (Atlanta, GA) | ⤷ Try a Trial |
| Narlaprevir | ⤷ Try a Trial | Anti-viral compounds | AbbVie Inc. (North Chicago, IL) | ⤷ Try a Trial |
| Narlaprevir | ⤷ Try a Trial | Anti-viral compounds | AbbVie Inc. (North Chicago, IL) | ⤷ Try a Trial |
| Narlaprevir | ⤷ Try a Trial | Combination formulation of two antiviral compounds | Gilead Pharmasset LLC (Foster City, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Narlaprevir
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Narlaprevir | European Patent Office | EP3004130 | 2033-06-05 | ⤷ Try a Trial |
| Narlaprevir | World Intellectual Property Organization (WIPO) | WO2014197578 | 2033-06-05 | ⤷ Try a Trial |
| Narlaprevir | Canada | CA2984421 | 2035-05-01 | ⤷ Try a Trial |
| Narlaprevir | China | CN107709344 | 2035-05-01 | ⤷ Try a Trial |
| Narlaprevir | European Patent Office | EP3288957 | 2035-05-01 | ⤷ Try a Trial |
| Narlaprevir | Mexico | MX2017013956 | 2035-05-01 | ⤷ Try a Trial |
| Narlaprevir | World Intellectual Property Organization (WIPO) | WO2016178876 | 2035-05-01 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
